UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability.

Its core business includes the development of devices for sleep apnea -- such as CPAP and APAP machines -- and digital health solutions. Key success factors for ResMed include maintaining ...

We think ResMed’s intangible brand has also enabled significant price premiums over less well ... device category and 30% higher in the CPAP category. This may reflect higher reimbursement ...

ResMed Inc . (NYSE:RMD) reported its financial results for the second quarter of fiscal year 2025, exceeding analysts' expectations with an earnings per share (EPS) of $2.43, surpassing the forecasted ...

In recent trading, shares of ResMed Inc. (Symbol: RMD) have crossed above the average analyst 12-month target price of $253.00, changing hands for $254.70/share. When a stock reaches the target an ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.